Navigation Links
BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
Date:4/21/2009

to identify the optimal dose of GALNS for future studies.

BioMarin has developed and manufactures two FDA-approved enzyme replacement therapies, one for the treatment of MPS I and one for the treatment of MPS VI. Naglazyme(R) (galsulfase) for MPS VI is wholly developed and commercialized by BioMarin. Aldurazyme(R) (laronidase) for MPS I is manufactured by BioMarin and marketed by Genzyme Corporation.

About MPS IVA

Mucopolysaccharidosis IVA (MPS IVA, also known as Morquio A Syndrome) is a disorder characterized by deficient activity of N-acetylgalactosamine 6-sulfatase (GALNS) causing excessive lysosomal storage of keratan sulfate (KS). This excessive storage causes a systemic skeletal dysplasia, short stature, and joint abnormalities, which limit mobility and endurance. Malformation of the thorax as well as macrophage dysfunction in the lung likely impairs respiratory function and contributes to sinopulmonary infections. Odontoid dysplasia and ligamentous laxity can commonly cause cervical spinal instability and potentially spinal cord compression. Other symptoms may include recurrent infections, hearing loss, corneal clouding, and heart valvular disease. Initial symptoms often become evident in the first five years of life. Depending on severity of the disorder, age of diagnosis will vary. Many patients become wheelchair dependent in their second decade of life and undergo numerous surgeries to alleviate life-threatening conditions caused by the underlying enzyme deficiency.

The incidence estimates for MPS IVA vary widely, between one in 200,000 live births to one in 300,000 live births. Approximately 400 patients worldwide have been identified and tracked through the International Morquio Organization (IMO) survey. There are already more MPS IVA patients identified through this registry than there are MPS VI patients being treated with Naglazyme worldwide. Based on the nu
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
2. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
3. BioMarin Announces FDA Approval for Kuvan
4. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
5. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
6. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
7. Osprey Pharmaceuticals U.S.A., Inc. Initiates Phase Ib Clinical Trial in IgA Nephropathy
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
10. Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
11. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/bf3b6l/electrocardiogram ) ... Devices - Global Trends, Estimates and Forecasts, 2012-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Global Electrocardiogram Devices (ECG) sector ... North America accounts for nearly ... Europe claims approximately 27% (2018). ...
(Date:12/15/2014)... 12, 2014 Research and Markets ... http://www.researchandmarkets.com/research/ms3j8c/cardiac ) has announced the addition of the ...  report to their offering. Global Guidewires sector is ... North America accounts for nearly 35% ... claims approximately 25% (2018). Asia-Pacific ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  Immune Pharmaceuticals Inc. ... that its Board of Directors has elected Mr. Daniel Kazado ... who continues as Chief Executive Officer of Immune. Mr. Kazado ... 2013. Immune,s new Chairman, Mr. Daniel Kazado ... shareholders and to continue to support the strategic vision of ...
Breaking Medicine Technology:Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4
... Pa., Aug. 9, 2011 Styron, the global ... rubber, announced an addition to its EMERGE™ Advanced ... PC/PET 9100CR Advanced Resin is a polycarbonate ... for medical equipment housing applications. (Logo: ...
... Inc. (Nasdaq: CYBX ) today announced that the company ... 2011 of its fiscal year ending April 27, 2012, on Thursday, ... conduct a conference call to discuss those results on the same ... Fiscal Year 2012 First Quarter Results Conference Call Instructions ...
Cached Medicine Technology:Styron Introduces Chemical Resistance Blends for Medical Housings 2Cyberonics to Report Fiscal Year 2012 First Quarter Results and Host Conference Call on August 25, 2011 2
(Date:12/17/2014)... News) -- Expectant parents should leave prenatal picture-taking to ... Use of ultrasound imaging and heartbeat monitors to ... the agency warns. "Although there is a ... imaging and heartbeat monitors, prudent use of these devices ... an FDA biomedical engineer, said in an agency news ...
(Date:12/17/2014)... Amy Norton HealthDay Reporter ... long been believed to improve overall health, but a growing ... the heart, a new review finds. In fact, the ... brisk walking, said lead researcher Paula Chu, a doctoral candidate ... review, of 37 clinical trials, found that people randomly assigned ...
(Date:12/15/2014)... NV (PRWEB) December 15, 2014 Veretekk.com, ... company, JM Ocean Avenue. JM Ocean Avenue has ... the Veretekk online automated marketing system. JM Ocean ... June 2014 merger of Ocean Avenue and JM International, ... than $2 Billion per year company. , “After nearly ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 OutMarket ... today released “ Social Media Cheat Sheets ,” a ... community that drives results on the top ten social ... program. It helps drive awareness, engagement, and customer service. ... marketers to make an impact on new networks and ...
(Date:12/15/2014)... Dallas,TX (PRWEB) December 15, 2014 The increase ... is one of the main factors which is contributing to ... used for the diagnosis and treatment of hearing loss and ... comprises of three parts - microphone, speaker and amplifier. The ... growth rate of 6.01% during the period from 2014 to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4
... with good health and vitality. However, just a small amount ... D. //It doesn't take much sunlight to make all the ... it takes to get a suntan. ,Recently, a study ... UV light (UVL) tanning behavior. For the study, researchers at ...
... survey conducted by Synovate India and sponsored by Colgate-Palmolive (India) ... and the latest toothpaste available in the market, //the level ... of those surveyed admitted that they have never been to ... that poor oral hygiene practices are resulting in a myriad ...
... global burden imposed by the widespread incidence of AIDS, ... //It has been estimated that one in every six ... initiative would focus on the efficacy of herbal remedies ... were considered out of which three have been approved. ...
... spatial processing, memory, and cognitive proficiency are consequences of ... than the general population,// yet the possible neurocognitive effects ... despite evidence that long-term smoking is associated with neurocognitive ... A research team from ...
... Florida doctors claim that some head and neck cancer patients ... a CT scan.// This scan can predict whether the cancer ... ,These findings were presented at the annual meeting of the ... M.D., a resident in radiation oncology at the UF Shands ...
... gynecomastia, and loss of sexual interest have often been ... reported in men who are long-term alcohol users,// with ... ethanol might cause gonadal disorders, including structural testicular changes ... T, which might be involved in the hypogonadism and ...
Cached Medicine News:Health News:Detrimental Effect Of Chronic Alcoholism On Male Fertility 2
... The MicroDigital IP 6.2 Series Image ... 3-chip camera for all surgical specialties. This ... camera functions such as brightness, enhancement, gain, ... your fingertips. Multiple-range image enhancement and adjustable ...
... ALU-2B Halogen Light Source is ... the addition of dual lamps ... This light source is ideal ... has the added feature of ...
Combination Ultrasonic and Pneumatic Urological Lithotriptor. Consists of four sizes of rigid pneumatic probes for use in the kidney, ureter and bladder....
All the power and performance of the STS - T but now available with a stand-alone 9" II C-Arm...
Medicine Products: